Bullous Pemphigoid

Description

Bullous pemphigoid (BP) is the most common form of autoimmune bullous dermatosis.

Clinical Features

Phenotypes and symptoms related to Bullous Pemphigoid

  • Recurrent infections
  • Diabetes mellitus
  • Weight loss
  • Erythema
  • Autoimmunity
  • Abnormal blistering of the skin
  • Eczema
  • Urticaria
  • Psoriasiform dermatitis
  • Macule

Incidence and onset information

— Based on the latest data available BULLOUS PEMPHIGOID have a estimated prevalence of 26 per 100k worldwide.
No data available about the known clinical features onset.

Researches and researchers

Doctors, researchs, and experts related to Bullous Pemphigoid extracted from public data.

Bullous Pemphigoid Experts map



Current Researchs and researchers

  • ROUEN — Pr Pascal JOLY

    Coordinator of expert centre - Clinical expert - Principal investigator of clinical trial - Investigator of research project

    • Institution/s:
      — CHU de Rouen
      — Clinique dermatologique, CHU de Rouen
      — INSERM U 905 IFRMP 23, Faculté de médecine et de pharmacie de Rouen
    • Research area/topic::

      Study of B clone specific of Desmogleines and antigens of bullous pemphigoid


  • GÖTTINGEN — Pr Ibrahim ADHAM

    Responsible for diagnostic tests - Investigator of research project

    • Institution/s:
      — Institut für Humangenetik der Universität Göttingen
    • Research area/topic::

      KFO 303: Pemphigoid Diseases - Molecular Pathways and their Therapeutic Potential : Genetics of Pemphigoid Diseases in human - DE


  • LÜBECK — Pr Detlef ZILLIKENS

    Coordinator of expert centre - Clinical expert - Principal investigator of clinical trial - Coordinator of research network - Director of department

    • Institution/s:
      — Universitätsklinikum Schleswig-Holstein - Campus Lübeck
      — Universitätsklinikum Schleswig-Holstein - Campus Lübeck
      — Klinik für Dermatologie, Allergologie und Venerologie, Universitätsklinikum Schleswig-Holstein - Campus Lübeck
    • Research area/topic::

      KFO 303: Pemphigoid Diseases - Molecular Pathways and their Therapeutic Potential


  • LÜBECK — Pr Enno SCHMIDT

    Clinical expert - Responsible for diagnostic tests - Investigator of research project - Director of laboratory

    • Institution/s:
      — Universitätsklinikum Schleswig-Holstein - Campus Lübeck
      — Klinik für Dermatologie, Allergologie und Venerologie, Universitätsklinikum Schleswig-Holstein - Campus Lübeck
      — Universitätsklinikum Schleswig-Holstein - Campus Lübeck
    • Research area/topic::

      KFO 303: Pemphigoid Diseases - Molecular Pathways and their Therapeutic Potential : The skin microbiome modulating Pemphigoid Diseases - DE


  • LÜBECK — Pr Ralf J. LUDWIG

    Investigator of research project - Coordinator of research network

    • Institution/s:
      — Universitätsklinikum Schleswig-Holstein - Campus Lübeck
      — Universitätsklinikum Schleswig-Holstein - Campus Lübeck
    • Research area/topic::

      DPem : Dimethylfumarate for the treatment of bullous pemphigoid -DE-


  • MARBURG — Pr Michael HERTL

    Coordinator of expert centre - Clinical expert - Investigator of research project - Coordinator of research network

    • Institution/s:
      — Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg
    • Research area/topic::

      Development of pathogenetic autoimmune reactions in bullous pemphigoid


Bullous Pemphigoid Recommended genes panels

Panel Name, Specifity and genes Tested/covered
Narcolepsy (HLA-DQB1 06:02) Genotyping.

By ARUP Laboratories, Molecular Genetics and Genomics (United States).

HLA-DQB1
Specificity
100 %
Genes
50 %
Celiac Disease (HLA-DQ2 and HLA-DQ8) Genotyping.

By ARUP Laboratories, Molecular Genetics and Genomics (United States).

HLA-DQA1, HLA-DQB1
Specificity
50 %
Genes
50 %
Celiac disease (HLA-DQ/DR).

By CGC Genetics (Portugal).

HLA-DQA1, HLA-DQB1
Specificity
50 %
Genes
50 %
Lactose intolerance (MCM6 gene) and Celiac disease (HLA-DQ2/ HLA-DQ8).

By CGC Genetics (Portugal).

HLA-DQA1, HLA-DQB1, MCM6
Specificity
34 %
Genes
50 %
Celiac Disease via Next Generation Sequencing HLA Typing.

By PreventionGenetics PreventionGenetics (United States).

HLA-DQA1, HLA-DQB1
Specificity
50 %
Genes
50 %
Narcolepsy Risk Factor.

By Bioscientia GmbH Center for Human Genetics (Germany).

HLA-DQB1, HLA-DRB1
Specificity
100 %
Genes
100 %
HLA DQ2/DQ8.

By Furst Medical Laboratories, FurstNAT (Norway).

HLA-DQA1, HLA-DQB1
Specificity
50 %
Genes
50 %
Celiac Disease (HLA-DQA1*05, HLA-DQB1*02, and HLA-DQB1*03:02) Genotyping.

By Molecular Genetics Laboratory Centro de Investigaciones Endocrinologicas "Dr. Cesar Bergada" (Argentina).

HLA-DQA1, HLA-DQB1
Specificity
50 %
Genes
50 %

You can get up to 2 more panels with our dedicated tool

Learn more

Sources and references

You can check the following sources for additional information.

ORPHANET MESH Genetic Syndrome Finder

If you liked this article maybe you will also find interesting the following in-depth articles about other rare diseases, like TOWNES-BROCKS SYNDROME 2; TBS2 THYROID DYSHORMONOGENESIS 3; TDH3 MACULAR DYSTROPHY, VITELLIFORM, 3; VMD3 CEREBRAL DYSGENESIS, NEUROPATHY, ICHTHYOSIS, AND PALMOPLANTAR KERATODERMA SYNDROME CHROMOSOME 17q12 DELETION SYNDROME KLIPPEL-FEIL SYNDROME 4, AUTOSOMAL RECESSIVE, WITH NEMALINE MYOPATHY AND FACIAL DYSMORPHISM; KFS4 NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE I; HMN1